(S)-(2-bromoquinolin-4-yl)((R)-1-tritylpiperidin-2-yl)methanol

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: (S)-(2-bromoquinolin-4-yl)((R)-1-tritylpiperidin-2-yl)methanol
• 英文别名: (S)-(2-bromoquinolin-4-yl) [(2R)-1-(triphenylmethyl)piperidin-2-yl]methanol；(S)-(2-bromoquinolin-4-yl)-[(2R)-1-tritylpiperidin-2-yl]methanol
• 化学式: C₃₄H₃₁BrN₂O
• 分子量: 563.537
• InChiKey: AQVCROCQEAPDBC-VTIYRKAUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8
• 重原子数：
  38
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  36.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (S)-(2-bromoquinolin-4-yl)((R)-1-tritylpiperidin-2-yl)methanol 在 盐酸 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium carbonate 作用下， 以 2-甲基四氢呋喃 、 乙醚 、 水 为溶剂， 反应 8.0h， 生成 (S)-(2-(4-chlorophenyl)quinolin-4-yl)((R)-piperidin-2-yl)methanol
  参考文献：
  名称：

  Therapeutic use of isomeric forms of 2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol

  摘要：

  本发明涉及2,4-二取代喹啉衍生物Vacquinol-1（NSC13316，（2-（4-氯苯基）喹啉-4-基）（哌啶-2-基）甲醇）的某些同分异构体形式，用于治疗全身性癌症，以及包含所述2,4-二取代喹啉衍生物Vacquinol-1的同分异构体形式的制药组合物，用于所述治疗。

  公开号：

  EP3064205A1
• 作为产物：
  描述：

  D-哌啶-2-甲酸 在 lithium aluminium tetrahydride 、 氯化亚砜 、 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 49.0h， 生成 (S)-(2-bromoquinolin-4-yl)((R)-1-tritylpiperidin-2-yl)methanol
  参考文献：
  名称：

  Therapeutic use of isomeric forms of 2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol

  摘要：

  本发明涉及2,4-二取代喹啉衍生物Vacquinol-1（NSC13316，（2-（4-氯苯基）喹啉-4-基）（哌啶-2-基）甲醇）的某些同分异构体形式，用于治疗全身性癌症，以及包含所述2,4-二取代喹啉衍生物Vacquinol-1的同分异构体形式的制药组合物，用于所述治疗。

  公开号：

  EP3064205A1

文献信息

• COMPOUNDS AND USE FOR TREATING CANCER
  申请人：GLIONOVA AB

  公开号：US20160214958A1

  公开（公告）日：2016-07-28

  The present invention relates to certain 2,4-disubstituted quinoline derivatives, to their therapy, as well as to pharmaceutical compositions comprising said compounds. More specifically the invention relates to certain 2,4-disubstituted quinoline derivatives or pharmaceutical compositions comprising said compounds for the treatment of cancers characterized by overactive Ras and/or Rac or signalling pathway.

  本发明涉及某些2,4-二取代喹啉衍生物及其治疗方法，以及包含该化合物的制药组合物。更具体地说，本发明涉及某些2,4-二取代喹啉衍生物或包含该化合物的制药组合物，用于治疗由过度活跃的Ras和/或Rac或信号通路所特征的癌症。
• CRYSTALLINE FORMS OF (R)-(2-(4-CHLOROPHENYL)QUINOLIN-4-YL)((S)-(PIPERIDIN-2-YL)METHANOL
  申请人：Glionova AB

  公开号：EP3064493A1

  公开（公告）日：2016-09-07

  The present invention relates to novel crystalline forms of Vacquinol-1, in particular novel crystalline forms of (R)-(2-(4-chlorophenyl)quinolin-4-yl)((S)-piperidin-2-yl)methanol and to methods for their preparation. The invention is also directed to pharmaceutical compositions containing at least one such crystalline form, therapeutic or prophylactic use of such crystalline forms and compositions and methods of preparing such crystalline forms.

  本发明涉及 Vacquinol-1 的新型结晶形式，特别是(R)-(2-(4-氯苯基)喹啉-4-基)((S)-哌啶-2-基)甲醇的新型结晶形式及其制备方法。 本发明还涉及含有至少一种此类结晶形式的药物组合物、此类结晶形式的治疗或预防用途以及制备此类结晶形式的组合物和方法。
• Development of Quinoline-Based Disruptors of Biofilm Formation Against <i>Vibrio cholerae</i>
  作者：Brian León、Jiunn C. N. Fong、Kelly C. Peach、Weng Ruh Wong、Fitnat H. Yildiz、Roger G. Linington

  DOI：10.1021/ol400150z

  日期：2013.3.15

  Biofilm formation is a major cause of bacterial persistence in nosocomial infections, leading to extended treatment times and increased rates of morbidity and mortality. Despite this, there are currently no biofilm inhibitors approved for clinical use. The synthesis and biological evaluation of a library of amino alcohol quinolines as lead compounds for the disruption of biofilm formation in Vibrio cholerae is now reported. Application of selective metal-halogen exchange chemistry installed both stereocenters in one step, to afford a simpler scaffold than the initial lead molecule, with an EC50 < 10 mu M.
• [EN] THERAPEUTIC USE OF ISOMERIC FORMS OF 2-(4-CHLOROPHENYL)QUINOLIN-4-YL)(PIPERIDIN-2-YL)METHANOL<br/>[FR] UTILISATION THÉRAPEUTIQUE DE FORMES ISOMÉRIQUES DU 2-(4-CHLOROPHÉNYL)QUINOLINE-4-YL)(PIPÉRIDINE-2-YL)MÉTHANOL
  申请人：GLIONOVA AB

  公开号：WO2016144241A1

  公开（公告）日：2016-09-15

  The present invention relates to certain isomeric forms of the 2,4-disubstituted quinoline derivative Vacquinol-1(NSC13316, (2-(4-chlorophenyl)quinolin-4- yl)(piperidin-2-yl)methanol), for use the in treatment of systemic cancer, as well as pharmaceutical compositions comprising said isomeric forms of the 2,4-disubstituted quinoline derivative Vacquinol-1 for the intended use.
• Therapeutic use of isomeric forms of 2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol
  申请人：Glionova AB

  公开号：EP3064205A1

  公开（公告）日：2016-09-07

  The present invention relates to certain isomeric forms of the 2,4-disubstituted quinoline derivative Vacquinol-1 (NSC13316, (2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol), for use the in treatment of systemic cancer, as well as pharmaceutical compositions comprising said isomeric forms of the 2,4-disubstituted quinoline derivative Vacquinol-1 for the intended use.

  本发明涉及2,4-二取代喹啉衍生物Vacquinol-1（NSC13316，（2-（4-氯苯基）喹啉-4-基）（哌啶-2-基）甲醇）的某些同分异构体形式，用于治疗全身性癌症，以及包含所述2,4-二取代喹啉衍生物Vacquinol-1的同分异构体形式的制药组合物，用于所述治疗。